Novartis Licenses Abogen's mRNA Autoimmune Drug for $7.8 Billion

Novartis AG has agreed to license a messenger RNA-based autoimmune therapy from China's Abogen Biosciences, in a deal that could be worth as much as $7.8 billion, Bloomberg reported on October 2, 2026.

What did Novartis and Abogen agree to?

Under the arrangement described by Bloomberg, the Swiss drugmaker will license rights to an mRNA-based therapy that Abogen has developed to treat autoimmune disease. Bloomberg's reporting establishes the license and the deal's potential total value; it does not detail the specific autoimmune condition the therapy targets, the clinical stage of the asset, or how the payments are structured.

How much could the deal be worth?

Bloomberg puts the deal's maximum value at $7.8 billion. The report describes that figure as an upper bound — standard language in pharmaceutical licensing agreements, which typically combine an upfront payment with additional sums tied to development, regulatory, and sales milestones. Bloomberg's dispatch does not break out how much of the $7.8 billion, if any, would be paid at signing versus contingent on future benchmarks.

Who is Abogen Biosciences?

Abogen Biosciences is identified in the Bloomberg report as a Chinese company and the originator of the mRNA-based therapy now licensed to Novartis. The report does not provide additional company background, such as founding date, headquarters city, or prior partnerships.

Novartis AG will license a messenger RNA-based autoimmune therapy from China's Abogen Biosciences, in a deal worth as much as $7.8 billion.

Why does an mRNA platform matter for autoimmune disease?

mRNA technology became widely known through COVID-19 vaccines, where it was used to prompt the body to produce a viral protein and trigger an immune response. Applying the platform to autoimmune disease — a category of conditions in which the immune system attacks the body's own tissue — represents a different therapeutic direction than vaccine development. Bloomberg's report confirms that the licensed asset falls into this autoimmune category but does not specify the mechanism or the particular disease target.

What is still unknown about the deal?

Several details common to pharmaceutical licensing announcements are not addressed in the available reporting: the breakdown of upfront versus milestone payments, the therapy's development stage, projected timelines for regulatory filings, and whether either company issued a statement beyond the terms Bloomberg confirmed. HTT News will update this report if Novartis or Abogen release additional terms through regulatory filings or company statements.

When was the deal reported?

Bloomberg's account was published October 2, 2026. No earlier announcement of the agreement from Novartis' or Abogen's own channels was available in the material reviewed for this report.